AstraZeneca PLC (AZN)

NASDAQ: AZN · IEX Real-Time Price · USD
78.71
+0.65 (0.83%)
At close: Jul 19, 2024, 4:00 PM
78.75
+0.04 (0.05%)
After-hours: Jul 19, 2024, 7:58 PM EDT
0.83%
Market Cap 244.04B
Revenue (ttm) 47.61B
Net Income (ttm) 6.33B
Shares Out 3.10B
EPS (ttm) 2.03
PE Ratio 38.97
Forward PE 16.31
Dividend $1.45 (1.84%)
Ex-Dividend Date Feb 22, 2024
Volume 2,675,557
Open 78.31
Previous Close 78.06
Day's Range 78.16 - 78.76
52-Week Range 60.47 - 80.86
Beta 0.15
Analysts Buy
Price Target 87.25 (+10.85%)
Earnings Date Jul 25, 2024

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]

Sector Healthcare
IPO Date May 12, 1993
Employees 89,900
Stock Exchange NASDAQ
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $87.25, which is an increase of 10.85% from the latest price.

Price Target
$87.25
(10.85% upside)
Analyst Consensus: Buy
Stock Forecasts

News

These Stocks Offer Gains Without the U.S. Political Drama

Keir Stamer's style is the polar opposite of Donald Trump. Many wondered if he was too boring to be U.K. Prime Minister.

Other symbols: DEOUL
2 days ago - Barrons

AstraZeneca Closes Acquisition of Amolyt Pharma

LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrin...

5 days ago - GlobeNewsWire

AstraZeneca's COVID prevention drug application gets EU fast-track assessment

AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.

19 days ago - Reuters

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infecti...

Other symbols: SNY
23 days ago - Reuters

Healthcare: Best strategies to invest in pharma stocks

Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names...

Other symbols: AMGNLLYMRKNVO
24 days ago - Yahoo Finance

Tanium Plays Critical Role in Supporting AstraZeneca's Mission to Deliver Life-Changing Medicines

KIRKLAND, Wash.--(BUSINESS WIRE)--Tanium today shared the success story of customer AstraZeneca in securing over 125,000 endpoints across 125 countries using the Tanium XEM platform.

24 days ago - Business Wire

China approves AstraZeneca's Tagrisso-chemo combo as first-line treatment

China has approved the use of AstraZeneca's blockbuster cancer drug Tagrisso in combination with chemotherapy as a first line of treatment for adults with a type of advanced lung cancer, the company s...

24 days ago - Reuters

AstraZeneca says Imfinzi fails in late-stage trial to treat type of lung cancer

AstraZeneca said on Tuesday its blockbuster cancer drug, Imfinzi, failed to improve disease-free survival in a late-stage trial to treat a type of early-stage lung cancer.

25 days ago - Reuters

AstraZeneca's breast cancer drug combination fails in late-stage trial

AstraZeneca said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patient...

4 weeks ago - Reuters

AstraZeneca's lung cancer drug approved by US FDA for combination chemotherapy treatment

AstraZeneca, the largest pharmaceutical group in Britain, announced that the U.S. Food and Drug Administration (FDA) has approved its lung cancer drug, Imfinzi, for use alongside other chemotherapy tr...

4 weeks ago - Invezz

IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with carboplatin and paclitaxel followed by IMFINZI monotherapy has been approved in the US as treatment for adult...

4 weeks ago - Business Wire

AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer

AstraZeneca said its blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer tha...

4 weeks ago - Reuters

FARXIGA approved in the US for the treatment of pediatric type-2 diabetes

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FARXIGA® (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycemic control in pediatric patients with type-2 d...

5 weeks ago - Business Wire

TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) has been accepted and granted Priority Review in the US for the treatment of adult...

5 weeks ago - Business Wire

Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big

Drugmakers released cancer data at ASCO, with AstraZeneca taking center stage. A report found that digital physical therapy tools provide clinical benefits.

6 weeks ago - CNBC

Nucleus RadioPharma Secures Series A Extension Funding with AstraZeneca Investment

ROCHESTER, Minn.--(BUSINESS WIRE)--Nucleus RadioPharma, the world's first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the closi...

6 weeks ago - Business Wire

We're in a difficult business but have the right level of confidence, says AstraZeneca CEO

AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.

6 weeks ago - CNBC Television

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer

AstraZeneca CEO Pascal Soriot joins 'Mad Money' host Jim Cramer to talk its lung cancer treatment, late stage drug development, and more.

6 weeks ago - CNBC Television

Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030

In a Tuesday interview with CNBC's Jim Cramer, AstraZeneca CEO Pascal Soriot explained why the drug maker believes it can almost double revenues by the end of the decade. AstraZeneca announced in late...

6 weeks ago - CNBC

AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4 ROCKV...

6 weeks ago - PRNewsWire

Cramer's Stop Trading: AstraZeneca

CNBC's Jim Cramer explains why he is keeping an eye on shares of AstraZeneca.

6 weeks ago - CNBC Television

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningfu...

6 weeks ago - Business Wire

IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ADRIATIC Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improv...

6 weeks ago - Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy

WILMINGTON, Del.--(BUSINESS WIRE)--Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant a...

6 weeks ago - Business Wire

ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy.

6 weeks ago - Business Wire